secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K/A
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-090702
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma reports H1 2023 net loss of $33M; cash at $2.6M with going-concern doubt
--------------------------------------------------------------------------------

- Net loss of $33.0M for six months ended June 30, 2023 vs $7.6M loss in H1 2022.
- Cash fell to $2.6M as of June 30, 2023 from $9.7M at Dec 31, 2022.
- Accumulated deficit reached $507.9M; auditor notes substantial doubt about going concern.
- Convertible notes total $134.4M ($73.4M current + $60.9M non-current) as of June 30, 2023.
- Business combination with Priveterra closed July 21, 2023; now listed on NYSE as AEON.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923090702/0001104659-23-090702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923090702/tm2323141d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-090702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer